Skip to main content
. 2007 Jul 18;2007(3):CD006063. doi: 10.1002/14651858.CD006063.pub2
Characteristic Kahn 2006 Ko 2006 Lebovitz 2001 Ovalle 2004 Philipps 2001 Raskin 2004
  I1: rosiglitazone max. 8 mg 
 C1: metformin max. 2 g 
 C2: glyburide max. 15 mg I1: rosiglitazone max. 8 mg 
 + (sulfonylurea +/‐ metformin) 
 C1: "bedtime insulin" 
 + (sulfonylurea +/‐ metformin) I1: rosiglitazone 4 mg 
 I2: rosiglitazone 8 mg 
 C1: placebo I1: rosiglitazone 8 mg 
 C1: insulin 70/30 I1: rosiglitazone 4 mg 
 I2: rosiglitazone 2 x 2 mg 
 I3: rosigllitazone 8 mg 
 I4: rosiglitazone 2 x 4 mg 
 C1: placebo I1: rosiglitazone 8 mg 
 C1: repaglinide 12 mg 
 C2: rosiglitazone 4 mg + repaglinide 6 mg
[n] of participants who died I1: 34 
 C1: 31 
 C2: 31 ? ? ? ? ?
[%] adverse events I1: 91.9 (1338/1456) 
 C1: 92.2 (1341/1454) 
 C2: 91.7 (1321/1441) I1: 7.1 
 C1: 10.7 I1: 73.1 (121/166) 
 I2: 74.3 (126/169) 
 C1: 69.9 (110/158) ? I1+ I2+ I3+I4: 75 
 (551/ 735) 
 C1: 71 (123/173) I1: 24 (15/62) 
 C1:37 (23/63) 
 C2: 64 (81/127)
[%] serious adverse events I1: 23.8 (346/1456) 
 C1: 22.8 (331/1454) 
 C2: 21.4 (308/1441) I1: 5.4 
 C1: 0 ? ? ? ?
[%] drop‐outs due to adverse events I1: 11.6 
 C1: 12.2 
 C2: 14.9 I1: 7.1 
 C1: 0 ? ? I1+I2 +I3 +I4: 5.6 (41/735) 
 
 C1: 10.8 (19/173) I1: 9.7 (6/62) 
 C1: 6.3 (4/63) 
 C2: 3.1 (4/127)
[%] oedema I1: 14.1 (205/1456) 
 C1: 7.2 (104/1454) 
 C2: 8.5 (123/1441) I1: 3.6 
 C1: 0 I1: 6 (10/166) 
 I2: 10.7(18/169) 
 C1:1.9 (3/158) ? I1: 5.2 (10/181) 
 I2: 4.1 (8/ 186) 
 I3: 6.4 (12/181) 
 I4: 6.6 (13/187) 
 C1: 1.6 (3/173) I1: 3 (2/62) 
 C1: 0 
 C2: 4 (5/125)
haemoglobin [g/dl] ? ? I1: ‐0.6 
 I2: ‐1.0 
 C1: ? ? I1+ I2+ I3+ I4 : 
 ‐0.5 to ‐ 0.9 (dosage dependent) 
 C: ? I1: ‐ 0.7 
 C1: 0 
 C2: ‐ 0.8
body weight [kg] ? ? I1: 1.6 
 I2: 3.5 
 C1: ‐1 ? I1: 1.2 
 I2: 1.5 
 I3: 2.6 
 I4: 3.3 
 C1: ‐ 0.9 I1: + 2.3 
 C1: +1.6 
 C2: + 4.4
body mass index (BMI) [kg/m2] (SD) ? I1: 0.9 (1.3 ) 
 C1: 0.8 (0.9) 
 
 change data after one year ? ? ? ?
[%] hypoglycaemic episodes I1: 9.8 (142/1456) 
 C1: 11.6 (168/1454) 
 C2: 38.7 (557/1441) I1: 0 
 C1: 8.9 ? ? ? I1: 2 (1/62) 
 C1: 6 (4/63) 
 C2: 9 (11/127)
[%] severe hypoglycaemic episodes I1: 0.1 (2/1456) 
 C1: 0.1 (1/1454) 
 C2: 0.6 (8/1441) I1: 0 
 C1: 0 ? ? ? I1: 0 
 C1: 0 
 C2: <1 (1 episode)
Notes ./. ./. ./. ./. ITT population C1: one patient with elevated liver transaminase (>3X normal limit)
[n] fractures (%) Men 
 I1: 32 (3.95) 
 C1: 29 (3.36) 
 C2: 28 (3.35) 
 
 Women 
 I1: 60 (9.30) 
 C1: 30 (5.08) 
 C2: 21 (3.47) 
 Lower limb 
 I1: 36 (5.58) 
 C1: 18 (3.05) 
 C2: 8 (1.32) 
 Upper limb 
 I1: 22 (3.41) 
 C1: 10 (1.69) 
 C2: 9 (1.49) 
 Spinal 
 I1: 1 (0.16) 
 C1: 1 (0.17) 
 C2: 1 (0.17)          
[%] hospitalization for any cause I1: 11.6 (169/1456) 
 C1: 11.8 (172/1454) 
 C2: 10.4 (150/1441)          
[%] cardiovascular disease, total events I1: 4.3 (62/1456) 
 C1: 4.0 (58/1454) 
 C2: 2.8 (41/1441)          
[%] congestive heart failure, investigator‐reported, total events I1: 1.5 (22/1456) 
 C1: 1.3 (19/1454) 
 C2: 0.6 (9/1441)          
[%] peripheral vascular disease, total events I1: 2.5 (36/1456) 
 C1: 1.9 (27/1456) 
 C2: 2.2 (31/1441)          
[%] gastrointestinal events, total events I1: 23.0 (335/1456) 
 C1: 38.3 (557/1456) 
 C2: 21.9 (316/1441)          
[%] weight gain, total events I1: 6.9 (100/1456) 
 C1: 1.2 (18/1456) 
 C2: 7.2 (104/1441)          
[%] haematocrit >= 5 percentage points below the reference range I1: 2.8 (41/1456) 
 C1: 1.5 (22/1456) 
 C2: 1.0 (14/1441)          
             
Footnotes
? = unclear; I = intervention; C = control